1. Home
  2. PBLS vs FA Comparison

PBLS vs FA Comparison

Compare PBLS & FA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$31.69

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Logo First Advantage Corporation

FA

First Advantage Corporation

HOLD

Current Price

$19.82

Market Cap

3.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBLS
FA
Founded
N/A
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.5B
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
PBLS
FA
Price
$31.69
$19.82
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$15.67
AVG Volume (30 Days)
451.4K
1.9M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
72.97
EPS
N/A
0.01
Revenue
N/A
$1,574,389,000.00
Revenue This Year
N/A
$8.42
Revenue Next Year
N/A
$7.26
P/E Ratio
N/A
$2,001.00
Revenue Growth
N/A
83.02
52 Week Low
$25.56
$8.82
52 Week High
$33.65
$22.78

Technical Indicators

Market Signals
Indicator
PBLS
FA
Relative Strength Index (RSI) 58.91 54.53
Support Level $26.83 $13.97
Resistance Level $33.65 $20.97
Average True Range (ATR) 2.52 0.91
MACD 0.18 -0.30
Stochastic Oscillator 74.69 25.84

Price Performance

Historical Comparison
PBLS
FA

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

About FA First Advantage Corporation

First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.

Share on Social Networks: